Diagnosing swine flu: the inaccuracy of case definitions during the 2009 pandemic, an attempt at refinement, and the implications for future planning

Andrew A. Mahony, Allen C. Cheng, Karen L. Olsen, Craig A. Aboltins, James F. P. Black, Paul D. R. Johnson, M. Lindsay Grayson, Joseph Torresi

Background At the onset of the pandemic H1N1/09 influenza A outbreak in Australia, health authorities devised official clinical case definitions to guide testing and access to antiviral therapy.

Objectives To assess the diagnostic accuracy of these case definitions and to attempt to improve on them using a scoring system based on clinical findings at presentation.

Patients/Methods This study is a retrospective case–control study across three metropolitan Melbourne hospitals and one associated community-based clinic during the influenza season, 2009. Patients presenting with influenza-like illness who were tested for H1N1/09 influenza A were administered a standard questionnaire of symptomatology, comorbidities, and risk factors. Patients with a positive test were compared to those with a negative test. Logistic regression was performed to examine for correlation of clinical features with disease. A scoring system was devised and compared with case definitions used during the pandemic. The main outcome measures were the positive and negative predictive values of our scoring system, based on real-life data, versus the mandated case definitions.

Results Both the devised scoring system and the case definitions gave similar positive predictive values (38–58% using ascending score groups, against 39–44% using the various case definitions). Negative predictive values were also closely matched (ranging from 94% to 73% in the respective score groups against 83–84% for the case definitions).

Conclusions Accurate clinical diagnosis of H1N1/09 influenza A was difficult and not improved significantly by a structured scoring system. Investment in more widespread availability of rapid and sensitive diagnostic tests should be considered in future pandemic planning.

Keywords Case definitions, influenza A H1N1/09 subtype, ROC curve.

Introduction Pandemic H1N1/09 influenza A virus (“swine flu”) swept across the world in 2009. It triggered widespread public health actions, infected millions, and ultimately led to more than 18,449 reported deaths from April 2009 to August 2010. Fortunately, H1N1/09 did not prove as virulent as other viruses such as highly pathogenic avian influenza (H5N1), upon which many national influenza pandemic preparation plans were based.

In Victoria, Australia, public health measures were guided by the state government endorsed “Victorian Health Management Plan for Pandemic Influenza,” which in turn was part of the “Australian Health Management Plan for Pandemic Influenza 2008,” the latter subsequently updated during the pandemic. Different phases of response, based on active surveillance to monitor disease transmission, were used to guide control measures; a working case definition of pandemic influenza, one of the key elements of surveillance, was devised by expert members of the Communicable Diseases Network Australia (CDNA), and this became a gateway to diagnostic testing and early use of antiviral therapy. Cases were required to meet clinical criteria – fever plus at least one upper respiratory tract symptom – plus have relevant travel or contact histories in order for testing to be authorized; later in the pandemic, when it was clear
that local community transmission was predominant, testing was only recommended for those with moderate to severe disease or those in particular high-risk groups: infants, healthcare workers, nursing home residents, and children in special development schools. Clinicians were surprised by the rigidity of the initial criteria, as it quickly became apparent that the vast majority of patients presenting to hospitals had not travelled from countries already recognized to have been affected by the pandemic.6

We sought to assess the validity of the mandated initial case definitions in patients tested for H1N1/09 influenza and in doing so, to inform future planning by public health leaders, laboratories and clinicians.

**Methods**

We conducted a retrospective case–control study of patients with suspected influenza who presented to the emergency departments or specially designated Influenza clinics of any of three Melbourne metropolitan hospitals or one associated community-based center, between April 30, 2009 and July 31, 2009. Patients were included if they had an acute respiratory tract illness where the treating clinician suspected influenza, and had undergone testing for H1N1/09 influenza A nucleic acid by polymerase chain reaction (PCR) via nose, throat, or nasopharyngeal swabs, using previously published methods, at the Victorian Infectious Diseases Reference Laboratory (VIDRL).6 Cases were those who tested positive for H1N1/09 influenza A, and controls were those who tested negative for influenza. Patients were identified prospectively to study investigators, as well as through searching microbiology laboratory results from the recruiting centers. Patients’ medical records were reviewed and patients were then contacted by telephone and interviewed using a standard questionnaire, with answers generated by a composite of file review and responses from this interview.

The questionnaire covered basic epidemiology (age, sex, and concurrent unwell family members), any symptoms at onset of influenza-like illness (ILI; fever, cough, sore throat, runny nose, myalgia, nasal congestion, diarrhea, and headache), comorbidities (chronic lung, heart or kidney disease, active malignancy, smoking, and immunosuppressed state), and pregnancy.

The case definitions used during the pandemic were first applied to the observed data in order to determine their positive and negative predictive values in our cohort. Two models were constructed to determine whether these case definitions could be improved upon by incorporating different clinical or epidemiological factors. First, a logistic regression was performed to examine for the correlation between clinical features, comorbidities, and other risk factors associated with influenza as compared with patients with negative influenza tests. For this analysis, we excluded patients with tests positive for non-H1N1/09 influenza A strains. Variables were selected for multivariable analysis by backwards stepwise regression with a threshold P-value for rejection of >0.2. Calibration, or the match between the model’s predicted and observed probabilities of H1N1/09 infection, was assessed using the Hosmer–Lemeshow goodness-of-fit test. This test compares the observed data against the model predicted values grouped into deciles, with a P < 0.05 suggesting poor fit.7 Discrimination, or the ability of the model to distinguish between patients with H1N1/09 infection and controls, was assessed by measuring the area under the receiver operator characteristic (ROC) curve.8 The AUROC represents the probability that a randomly selected subject with influenza had a higher score than a randomly selected subject without influenza.

Second, a summary scoring system was constructed from the regression coefficients using the factors found to be most strongly associated with outcome on multivariable analysis, and calibration and discrimination were assessed similarly. Regression coefficients, which are the natural logarithm of the odds ratio, were used so that an additive score could be constructed. All statistical analyses were performed using Stata, version 10.1 (StataCorp, College Station, TX, USA).

Ethics approval for this study was gained from the relevant ethical review board of each hospital: Austin Hospital, Northern Health and Alfred Hospital. Verbal consent to collect and analyze data was provided by all patients included in the study.

**Results**

Across the study centers, 818 patients were recruited. Table 1 lists enrolled patients’ characteristics. Patient disposition, isolation, and antiviral therapy have been described previously.9 A total of 253 patients (31%) were tested after more than 3 days’ duration of symptoms, with 77 (30%) of these positive for H1N1/09 infection. The performance of the CDNA case definitions in our cohort is shown in Table 2. Case definition one gave the highest positive predictive value, but this was only 44%; all three definitions had similar negative predictive values (83–86%). Univariate and multivariable logistic regression analyses are given in Table 3. Four symptoms – fever, cough, headache, and myalgia – as well as symptom combinations, younger age, and having a family member with ILI appeared to be significantly predictive of H1N1/09 infection while being immunosuppressed was a negative predictor on univariate analysis. On multivariable analysis, combinations of symptoms (e.g. fever and cough) were no better than individual symptoms using a variety of models and so were not included in the final regression; fever and cough were the
only significant predictive symptoms, whereas diarrhea was negatively associated. Pregnancy emerged as a significant variable and younger age remained important. Male gender appeared to be significant, but as we did not think this was plausible given the lack of evidence in the literature, this variable was removed from the model; its removal did not have any significant impact on the other variables’ coefficients (data not shown). Goodness of fit of the multivariable logistic regression model was adequate for predicting H1N1\textsubscript{P\&D} infection (Hosmer–Lemeshow test, \(P = 0.35\)), and the probability of H1N1\textsubscript{P\&D} infection increased with each decile, from 7% in the lowest decile to 81% in the highest decile. The AUROC curve was 0.75 (95% confidence interval, 0.71–0.79), indicating fair discrimination of this regression model (Figure 1).

The risk factor scoring system is shown in Table 4; for convenience, all regression coefficients were multiplied by ten to formulate each score. Scores were then stratified into groups, with the probability that tested patients had H1N1\textsubscript{P\&D} infection rising with increasing score (Table 5). Shortcomings in discrimination of the scoring system were apparent in the AUROC curve of 0.73 (95% confidence interval, 0.69–0.76, Figure 1), indicating that an eight-variable scoring system did not give sufficient power to accurately diagnose H1N1\textsubscript{P\&D} infection during a pandemic (\(P = 0.42\) comparing the two models’ AUROC).

Table 1. Patients’ characteristics

| Variable               | FluA negative \(n = 500\) (%) | H1N1\textsubscript{P\&D} positive \(n = 265\) (%) | FluA positive \(n = 53\) (%)* |
|------------------------|---------------------------------|-----------------------------------------------|-------------------------------|
| Female:male            | 272:228 (54:46)                 | 132:133 (50:50)                               | 20:33 (38:62)                 |
| Age 0–9 \((n = 129)\)  | 81 (16:2)                       | 35 (13:2)                                     | 13 (24:5)                     |
| Age 10–29 \((n = 330)\)| 166 (33:2)                      | 148 (55:8)                                    | 16 (30:2)                     |
| Age 30–59 \((n = 285)\)| 197 (39:4)                      | 72 (27:2)                                     | 16 (30:2)                     |
| Age 60–89 \((n = 74)\) | 56 (11:2)                       | 10 (3:8)                                      | 8 (15:1)                      |
| Chronic lung disease   | 133 (26:6)                      | 68 (25:7)                                     | 19 (35:8)                     |
| Smoking                | 81 (16:2)                       | 30 (11:3)                                     | 8 (15:1)                      |
| Heart disease          | 58 (10:8)                       | 21 (7:9)                                      | 7 (13:2)                      |
| Diabetes mellitus      | 26 (5:2)                        | 13 (4:9)                                      | 2 (3:8)                       |
| Immunosuppressed       | 77 (15:4)                       | 25 (9:4)                                      | 3 (5:7)                       |
| Chronic kidney disease | 22 (4:4)                        | 11 (4:2)                                      | 1 (1:9)                       |
| Active malignancy      | 41 (8:2)                        | 12 (4:5)                                      | 2 (3:8)                       |
| Pregnancy              | 18 (3:6)                        | 13 (4:9)                                      | 1 (1:9)                       |

*H3N2 influenza A was also circulating within Australia during the 2009 pandemic.

Table 2. Australian case definitions used for H1N1\textsubscript{P\&D} influenza and usefulness in the study cohort (with 95% confidence intervals)

| Definition       | Symptoms/signs                                                                 | Epidemiology                                                                 | Sensitivity   | Specificity | Predictive values       |
|------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------|-------------|-------------------------|
| Suspected case   | 1. Acute febrile respiratory illness, with at least one of rhinorrhea, nasal congestion, sore throat, or cough <br>2. As above | Onset within 7 days of travel to Mexico, USA, Canada (and other countries with evidence of local transmission) | 85% (80–89%) | 43% (39–48%) | PPV 44% (40–48%) <br>NPV 84% (79–88%) |
| Probable case    | 3. As above, for which no other cause is identified | – | 89% (85–93%) | 27% (23–31%) | PPV 39% (35–43%) <br>NPV 83% (76–88%) |
| Confirmed case   | Positive laboratory test: specific PCR, isolation of virus, viral sequencing | Gold standard* | 93% (89–96%) | 23% (19–27%) | PPV 39% (35–43%) <br>NPV 86% (79–91%) |

*While viral culture and sequencing are described in this definition as gold standards of a confirmed case, these techniques are not in clinical use and are of lower sensitivity than PCR. PPV, positive predictive value; NPV, negative predictive value.
Table 3. Univariate and multivariable logistic regression, H1N1:09 versus influenza negative: clinical and epidemiological features

| Variable                        | Regression coefficient | 95% confidence intervals | P-value | Adjusted regression coefficient | 95% confidence intervals | P-value |
|---------------------------------|------------------------|---------------------------|---------|---------------------------------|---------------------------|---------|
| Fever                           | 1.86                   | 1.38–2.34                 | <0.001  | 1.89                            | 1.36–2.42                 | <0.001  |
| Cough                           | 0.61                   | 0.24–0.98                 | 0.001   | 0.56                            | 0.13–0.98                 | 0.011   |
| Sore throat                      | 0.02                   | -0.29–0.33                | 0.92    | Dropped (P > 0.2)                |                           |         |
| Runny nose                       | 0.03                   | -0.28–0.34                | 0.84    | Dropped (P > 0.2)                |                           |         |
| Nasal congestion                | -0.28                  | -0.59–0.03                | 0.07    | -0.42                           | -0.79–0.06                | 0.023   |
| Diarrhea                         | -0.16                  | -0.55–0.23                | 0.41    | -0.47                           | -0.93–0.02                | 0.040   |
| Headache                         | 0.55                   | 0.24–0.87                 | 0.001   | 0.49                            | 0.12–0.86                 | 0.010   |
| Myalgia                          | 0.50                   | 0.15–0.85                 | 0.005   | Dropped (P > 0.2)                |                           |         |
| Fever + cough                    | 1.22                   | 0.89–1.56                 | <0.001  | Not included                     |                           |         |
| Fever + headache                 | 1.04                   | 0.72–1.36                 | <0.001  | Not included                     |                           |         |
| Fever + myalgia                  | 1.00                   | 0.53–1.47                 | <0.001  | Not included                     |                           |         |
| Fever + cough + headache         | 1.05                   | 0.73–1.38                 | <0.001  | Not included                     |                           |         |
| Fever + cough + headache + myalgia| 1.32               | 0.65–1.99                 | <0.001  | Not included                     |                           |         |
| Male                             | 0.18                   | -0.11–0.48                | 0.23    | Not included                     |                           |         |
| Chronic lung disease             | -0.04                  | -0.38–0.30                | 0.82    | Dropped (P > 0.2)                |                           |         |
| Smoking                          | -0.43                  | -0.88–0.01                | 0.06    | Dropped (P > 0.2)                |                           |         |
| Heart condition                  | -0.34                  | -0.87–0.18                | 0.20    | Dropped (P > 0.2)                |                           |         |
| Diabetes mellitus                | -0.06                  | -0.75–0.62                | 0.86    | Dropped (P > 0.2)                |                           |         |
| Immunosuppressed                 | -0.56                  | -1.04–0.09                | 0.02    | Dropped (P > 0.2)                |                           |         |
| Chronic kidney disease           | -0.06                  | -0.80–0.68                | 0.87    | Dropped (P > 0.2)                |                           |         |
| Active malignancy                | -0.63                  | -1.29–0.03                | 0.06    | Dropped (P > 0.2)                |                           |         |
| Pregnant                         | 0.32                   | -0.41–1.05                | 0.39    | 1.24                            | 0.38–2.10                 | 0.005   |
| Healthcare worker                | -0.13                  | -0.66–0.38                | 0.60    | Dropped (P > 0.2)                |                           |         |
| Family member with ILI           | 0.37                   | 0.07–0.68                 | 0.02    | 0.37                            | 0.02–0.72                 | 0.041   |
| Age 0–4 years                    | -0.66                  | -1.32–0.00                | 0.05    | Dropped (P > 0.2)                |                           |         |
| Age 5–18 years                   | 0.89                   | 0.56–1.22                 | <0.001  | 0.88                            | 0.50–1.26                 | <0.001  |
| Age 19–41 years                  | 0.00                   | -0.30–0.31                | 0.98    | Dropped (P > 0.2)                |                           |         |
| Age 42–65 years                  | -0.52                  | -0.93–0.12                | 0.01    | Dropped (P > 0.2)                |                           |         |
| Age 66+ years                    | -1.27                  | -2.08–0.46                | 0.002   | Dropped (P > 0.2)                |                           |         |

Discussion

We found that the application of case definitions, presence of single or multiple symptoms of ILI with or without limited additional epidemiology, and a scoring system derived from a large cohort of patients were of limited utility in accurate diagnosis of H1N1 pandemic influenza during the 2009 Australian influenza season.

Case definitions, as devised by the CDNA, were quite sensitive (85–93%, depending on the specific definition) but suffered from poor specificity. These findings suggest that for every 100 patients meeting the various case definitions, between 54 and 61 patients without influenza were treated and/or recommended to remain in isolation, and for every 100 patients tested who did not meet the case definition, between 14 and 17 patients were found to have influenza. In the early phases of a future
Our univariate logistic regression suggested four ILI symptoms classic for influenza – fever, cough, headache and myalgia – increased the likelihood of confirmed H1N1, with odds ratios >1.5 (regression coefficients >0.4). This is in broad agreement with the one published systematic review of the operating characteristics of signs and symptoms of influenza.\textsuperscript{15} Combinations of these symptoms, therefore, appeared to be significantly predictive. However, this was not borne out on multivariable analysis, with each individual symptom outperforming combinations in forming a predictive model. It is likely that using combinations of symptoms introduces additional confounding to such models. We were surprised and interested to find that sore throat, runny nose, and myalgia were not associated with H1N1 and that nasal congestion and diarrhea were negatively associated. This is in contrast with early reports of the clinical presentation of H1N1, where gastrointestinal symptoms were noted in a significant number of cases, but consistent with other Australian case series.\textsuperscript{16,17}

The strongest risk factors on multivariable regression for H1N1 influenza in the study cohort were not otherwise surprising. The unusual age distribution of H1N1 influenza – with older adults likely to have had a degree of cross-protection from exposure to previous pandemic virus strains – is reflected in the risk of being a child aged between 5 and 18 years of age in our cohort.\textsuperscript{18} Pregnancy has also been well described as a risk factor for hospitalization and death.\textsuperscript{19} In a previous H3 influenza epidemic in Canada, fever and cough were similarly shown to be the only symptoms predictive of a positive test result.\textsuperscript{20}

We developed a scoring system using eight factors in an attempt to improve on the accuracy of the case definitions. While others have devised a simple score incorporating clinical and laboratory data in determining the likelihood of H1N1 pneumonia compared to other causes of community-acquired pneumonia, or the need for hospitalization,
to the best of our knowledge, this is the first scoring system based entirely on variables immediately available to the clinician.\textsuperscript{21,22} The scoring system marginally outperformed the case definitions – score group 3, for example, had equivalent or superior predictive values to any of the CDNA definitions – and was of similar discrimination to the logistic regression (AUROC 0.73 versus 0.75). However, the system is relatively cumbersome and has not been externally validated. We do not believe that it offers any significant advantages for clinicians or public health practitioners and highlights the inability of clinical and epidemiological features to reliably predict H1N1 influenza.

Our study has several limitations. Data were collected retrospectively, potentially introducing recall bias although contemporaneous medical records were used where possible to validate the information collected. There was a bias at the referring centers to test only those patients meeting a case definition, as the testing reference laboratory was required to reject other samples in order to meet demand during the pandemic. This would have tended to improve the accuracy of the case definitions, but we were not able to identify patients who either did not have a sample collected or whose sample was not tested, to verify this. Patients were not excluded from our study based on their duration of symptoms prior to being tested. As the sensitivity of PCR-based testing for influenza wanes with time from onset of illness, this could have potentially led to misclassification of some cases into the control group; nonetheless, we found a significant proportion of patients tested beyond 3 days of illness to have H1N1\textsubscript{2009} infection, consistent with other studies demonstrating PCR-positivity well beyond this time period.\textsuperscript{23} Inclusion of overweight, based on Body Mass Index, may have added discrimination to our model as morbid obesity has emerged as a risk factor for severe disease.\textsuperscript{24} Ideally, we would have used a separate cohort of patients to validate our model but had insufficient numbers to do so; in light of its limited advantages over the case definitions, we have not gone on to do this using patients from subsequent influenza seasons.

We believe that our results have important implications for future pandemic planning. As this and previous studies have shown, clinical signs cannot be used to reliably rule in or rule out newly emerged influenza. The effectiveness of public health measures based on case definitions is likely to be impaired by the lack of sensitivity and specificity of these definitions. Testing for influenza should not be restricted to patients based on the presence or absence of particular symptoms or epidemiological risk factors, particularly where the results of testing may have implications for the management of individual patients. To circumvent the inherent problems in the accuracy of case definitions for pandemic influenza, investment in the more widespread availability of accurate diagnostics, and the ability to rapidly turn around the results of such testing, must be considered a priority. Cost-benefit analyses of the impact of rapid diagnostics on the spread of pandemic influenza, comparing high-risk groups to larger populations, would aid in determining the feasibility of such a strategy.

Acknowledgements

The authors are grateful to the clinical research nursing staff at the study sites who administered questionnaires to study participants.

This project was funded by an Australian Commonwealth Government National Health and Medical Research Council (NHMRC) Strategic Award.

Conflicts of interest

AC is an investigator on a study to examine the adverse events of influenza vaccine, funded by CSL Ltd, the manufacturer of the vaccine. AC has not received any direct funding from any pharmaceutical company and was supported by a National Health and Medical Research Council (NHMRC) training fellowship.

References

1 World Health Organisation. World Health Organisation: Pandemic (H1N1) 2009 – update 112. Available at http://www.who.int/csr/don/2010_08_06/en/index.html (accessed April 2011).
2 Victorian Department of Human Services: victorian health management plan for pandemic influenza. State of Victoria, 2007. Available at http://www.health.vic.gov.au/__data/assets/pdf_file/0017/54503/Victorian_health_management_plan_for_pandemic_influenza.pdf (accessed April 2011).
3 Commonwealth of Australia. Australian Government Department of Health and Ageing: australian health management plan for pandemic influenza. Canberra: Commonwealth of Australia, 2009. Available at http://www.flupandemic.gov.au/internet/panflu/publishing.nsf/Content/ahmppi-2009-l (accessed April 2011).
4 Fielding JE, Higgins N, Gregory JE et al. Pandemic H1N1 influenza surveillance in Victoria, Australia, April – September 2009. Euro Surveill 2009; 14:Pi: 19368.
5 Lester R, Moran R. Pandemic H1N1 2009 influenza (human swine flu) – the Victorian Government’s response. Vic Inf Dis Bull 2009; 12:43–45.
6 Centers for Disease Control and Prevention: cDC protocol of real-time RT-PCR for influenza A (H1N1) 2009. Available at: http://www.who.int/csr/resources/publications/swineflu/realtimempc/min/pdf/index.html (accessed April 2011).
7 Hosmer DW, Lemeshow S Applied logistic regression. 2nd edn. New York: Wiley, 2000.
8 Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361–387.
9 Teh B, Olsen K, Black J et al. Impact of swine influenza and quarantine measures on patients and households during the H1N1/09 pandemic. Scand J Infect Dis 2012; 44:289–296.
10 Bradt DA, Epstein J. The rational clinician in a pandemic setting. Med J Aust 2010; 192:1–3.
11 Smit PM, Limper M, van Gorp EC et al. Adult outpatient experience of the 2009 H1N1 pandemic: clinical course, pathogens, and evaluation of case definitions. J Infect 2011; 62:371–378.
12 Kasper MR, Wierzbka TF, Sovann L, Blair PJ, Putnam SD. Evaluation of an influenza-like illness case definition in the diagnosis of influenza among patients with acute febrile illness in Cambodia. BMC Infect Dis 2010; 10:320.
13 Stein J, Louie J, Flanders S et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. Ann Emerg Med 2005; 46:412–419.
14 Ruest A, Michaud S, Deslandes S, Frost EH. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003; 41:3487–3493.
15 Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA 2005; 293:987–997.
16 Centers for Disease Control and Prevention: CDC H1N1 flu update May 8 2009: US human cases of H1N1 flu infection. http://cdc.gov/h1n1flu/updates/050809.htm (accessed April 2011).
17 Looker C, Carville K, Grant K, Kelly H. Influenza A (H1N1) in Victoria, Australia: a community case series and analysis of household transmission. PLoS One 2010; 5:e13702.
18 Novel swine-origin influenza A (H1N1) virus investigation team, Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605–2615.
19 Louie JK, Acosta M, Winter K et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302:1896–1902.
20 Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000; 31:1166–1169.
21 Beswick T, Myles P, Greenwood S et al. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. Thorax 2011; 66:247–252.
22 Rodriguez-Noriega E, Gonzalez-Diaz E, Morfin-Otero R et al. Hospital triage system for adult patients using an influenza-like illness scoring system during the 2009 pandemic – Mexico. PLoS One 2010; 5:e10658.
23 Sues B, Buchholz U, Dupke S et al. Shedding and transmission of novel influenza virus A/H1N1 infection in households – Germany, 2009. Am J Epidemiol 2010; 171:1157–1164.
24 van Kerkhove MD, Vandermaele KA, Shirde V et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8:e1001053.